Novartis Challenges Gleevec Patent Block In India

Law360, New York (August 14, 2006, 12:00 AM EDT) -- Less than a year after India’s Patent Controller denied Novartis AG's patent application for the cancer treatment Gleevec, the Swiss-based pharmaceutical company is railing against the rejection.

Novartis recently filed multiple writs at the Madras High Court against the Patent Controller's decision to reject its patent application and is also seeking an interim stay, the Hindu Business Line reported this week.

The Chennai Patent Office rejected Novartis’ application in January on the grounds that Gleevec was not significantly different in properties from an already existing compound....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.